Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Facial Plastic Surgicenter Ltd

Neither a doctor nor a teaching hospital

Research payments

$698,734

91 payments

Through program year 2025, Facial Plastic Surgicenter Ltd is reported as receiving $698,734 in research payments, across 91 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $286,747 33
2024 Research $119,493 8
2023 Research $45,901 11
2022 Research $171,995 28
2020 Research $18,926 6
2019 Research $55,673 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $532,219 70 payments
  2. Galderma Laboratories, L.P. $91,916 10 payments
  3. Allergan Inc. $74,599 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $139,804 13 payments
  2. A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $121,412 22 payments
  3. A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness and safety of GP0112 for cheek augmentation, midface volumization and correction of midface contour deficiencies $91,916 10 payments
  4. JUVEDERM VOLITE XC Injectable Gel for Fine Lines on the Cheek $74,599 11 payments
  5. A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence $70,006 13 payments
  6. M21-841 NOA Volume - Mid Face US Pivotal Study $47,034 8 payments
  7. M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $43,459 3 payments
  8. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $36,388 1 payment
  9. M21-841 - M21-841 NOA Volume - Mid Face US Pivotal Study $25,576 2 payments
  10. The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. $13,731 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record